Exclusive Sponsor-Accounting Firm
Deloitte is one of the world’s largest networks of accounting and consulting firms (“Big 4”). Deloitte is the brand under which about 286,200 dedicated professionals in independent firms throughout the world collaborate to provide audit, consulting, tax, and advisory services to many of the world’s most admired brands, including 85% of the Fortune 500. Our people work across more than 20 industry sectors with one purpose: to deliver measurable, lasting results. We help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society. Clients count on Deloitte to help them transform uncertainty into possibility and rapid change into lasting progress. Our people know how to anticipate, collaborate, and innovate, and create opportunity from even the unforeseen obstacle.
Exclusive Sponsor-Law Firm
Cooley is a full service global law firm, having more than 900 lawyers across 13 offices in China, Europe and the United States. For over 40 years, Cooley has played an instrumental role in the growth of many of the most sophisticated companies in the life sciences industry, focusing on corporate partnering, licensing, complex mergers, acquisitions and disposition transactions, local and cross-border intellectual property issues, regulatory counselling, capital markets, supply and distribution arrangements and other commercial transactions. Our experience representing life sciences companies and investors also gives us insight into financings of companies at all stages of development.
We have been advising on Greater China-related matters over three decades and recently expanded our Asia-Pacific presence by launching the Beijing office. It is Cooley’s 13th office worldwide and its second in China, having opened in Shanghai in 2011.
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
Dyadic International (Nasdaq: DYAI) is a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.
Our lead microbial gene expression and protein production platform, the C1 technology, is based on the highly productive and scalable industrially proven fungus Thermothelomyces heterothallica, is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.
Dyadic is also developing the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies to enable our partners and collaborators to develop effective preventative and therapeutic treatments in developed and emerging countries.
To learn more about how Dyadic is helping to bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit www.dyadic.com.